Compare · AGL vs CCEL
AGL vs CCEL
Side-by-side comparison of agilon health inc. (AGL) and Cryo-Cell International Inc. (CCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and CCEL operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $1.49B, about 17.8x CCEL ($83.3M).
- Over the past year, AGL is up 257.6% and CCEL is down 5.7% - AGL leads by 263.3 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- AGL has more recent analyst coverage (25 ratings vs 0 for CCEL).
- Company
- agilon health inc.
- Cryo-Cell International Inc.
- Price
- $84.92-3.81%
- $4.15-1.89%
- Market cap
- $1.49B
- $83.3M
- 1M return
- -4.66%
- -6.11%
- 1Y return
- +257.58%
- -5.68%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 0
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest AGL
- agilon health Sets Date to Report Third Quarter 2026 Financial Results
- agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO
- agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO
- agilon health upgraded by Bernstein with a new price target
- agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO
- agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference
- agilon health to Participate in Upcoming Conferences
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 17 shares, decreasing direct ownership by 0.12% to 14,152 units (SEC Form 4) (withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
Latest CCEL
- SEC Form DEF 14A filed by Cryo-Cell International Inc.
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results
- SEC Form 8-K filed by Cryo-Cell International Inc.
- Chairman, Co-CEO Portnoy David acquired $799,995 worth of shares (600,191 units at $1.33) and disposed of $799,995 worth of shares (600,191 units at $1.33), decreasing direct ownership by 71% to 247,438 units (SEC Form 4)
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American